Previous Article | Next Article 
Infection and Immunity, September 1998, p. 4169-4175, Vol. 66, No. 9
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Ferrous Iron Uptake in Cryptococcus
neoformans
Eric S.
Jacobson,*
Asha Prasad
Goodner, and
Karin J.
Nyhus
Research Service, McGuire Veterans Affairs
Medical Center, Richmond, Virginia 23249, and Department of
Internal Medicine, Virginia Commonwealth University, Richmond,
Virginia 23298-0049
Received 13 February 1998/Returned for modification 21 March
1998/Accepted 1 June 1998
 |
ABSTRACT |
Previous studies have implicated ferric reduction in the iron
uptake pathway of the opportunistic pathogen Cryptococcus
neoformans. Here we studied iron uptake directly, using
55Fe in the presence of reductants. Uptake was linear with
respect to time and number of yeast cells. The plot of uptake versus
concentration exhibited a steep rise up to about 1 µM, a plateau
between 1 and 25 µM, and a second steep rise above 25 µM,
consistent with high- and low-affinity uptake systems. A
Km for high-affinity uptake was estimated to be
0.6 µM Fe(II); 1 µM was used for standardized uptake assays. At
this concentration, the uptake rate was 110 ± 3 pmol/106 cells/h. Iron repletion (15 µM) and copper
starvation drastically decreased high-affinity iron uptake.
Incubation at 0°C or in the presence of 2 mM KCN abolished
high-affinity iron uptake, suggesting that uptake requires metabolic
energy. When exogenous reducing agents were not supplied and the
culture was washed free of secreted reductants, uptake was reduced by
46%; the remaining uptake activity presumably was dependent upon the
cell membrane ferric reductase. Further decreases in free Fe(II) levels
achieved by trapping with bathophenanthroline disulfonate or
reoxidizing with potassium nitrosodisulfonate reduced iron uptake very
drastically, suggesting that it is the Fe(II) species which is
transported by the high-affinity transporter. The uptake of Fe was
stimulated two- to threefold by deferoxamine, but this increment could
be abolished by copper starvation or inhibition of the ferric reductase
by Pt, indicating that Fe solubilized by this molecule also entered the
reductive iron uptake pathway.
 |
INTRODUCTION |
Iron is required for oxidoreductase
enzymes in almost all living organisms. Although iron is widely
distributed in the environment, under neutral pH and aerobic conditions
oxidation of iron to poorly soluble Fe(III) causes ambient
concentrations to be very low. Microbes mobilize environmental iron for
uptake according to one of three basic strategies: by secreting
iron-chelating chemicals, by reducing insoluble environmental Fe(III)
to soluble Fe(II), or by expressing receptors and deferration
mechanisms for iron-containing proteins. The most widely studied
microbial iron uptake systems use secreted hydroxamate or catecholate
Fe(III) chelators, termed siderophores, and cell surface receptors
for the ferrated complex (21). One such siderophore,
deferoxamine (Desferal; Ciba-Geigy), is manufactured by
fermentation and is used clinically to mobilize trivalent metals.
Saccharomyces cerevisiae (16), Listeria
monocytogenes (5), Legionella pneumophila
(14), and higher plants (18, 23) use the
second strategy, reducing Fe(III) to Fe(II) prior to uptake of the
iron. The obligate pathogens Neisseria gonorrhoeae and
Neisseria meningitidis use the third strategy, binding and deferrating human transferrin and lactoferrin (19);
Hemophilus influenzae scavenges iron directly from heme and
hemoglobin (24).
Iron uptake mechanisms in pathogenic fungi are incompletely understood.
Hydroxamate siderophores have been detected in culture supernatants of
Histoplasma capsulatum (2). Rhizopus
species express surface receptors for ferri-deferoxamine but do not
secrete hydroxamate siderophores (1); thus,
deferoxamine represents an iron uptake-related vitamin in
Rhizopus, as it does in the pathogenic bacterium
Yersinia enterocolitica (25). In
Cryptococcus neoformans, deferoxamine stimulates
growth in the presence of iron starvation, but this fungus does
not secrete Fe(III) chelators, nor does it express a specific
transferrin receptor (12, 13). Rather, C. neoformans and Candida albicans reduce extracellular Fe(III) to the much more soluble form, Fe(II), like S. cerevisiae, and are presumed to transport nascent Fe(II)
into their cells (20, 22).
In what has been termed nutritional immunity, vertebrates use
unsaturated transferrins to withhold their iron from microbes and
respond to infections by further sequestering their stores of iron,
even to the point of anemia (3). This inference is supported
by the observation that saturation with physiologic iron chelators
leads to opportunistic infections (28). It has been
hypothesized that the administration of therapeutic iron-sequestering agents may further protect host iron stores and thereby alleviate infections. Such compounds are being actively sought, but currently the
only chelator which can be safely administered is deferoxamine, a
microbial hydroxamate siderophore. One might expect that this compound
would sequester iron and block iron uptake by microbes which lack
receptors for the iron chelate; however, the compound also might be
predicted to stimulate uptake in microbes which express such receptors.
Indeed, it has been found that the administration of deferoxamine
alleviates malaria (9) but promotes opportunistic infections
by Rhizopus species (1). Thus, microbial iron
uptake mechanisms can powerfully affect the host-parasite balance, and understanding them has the potential to lead to better management of
infections.
C. neoformans is the etiologic agent of a meningitis
which complicates many immunodeficiency diseases, including 10 to 20% of those resulting from the human immunodeficiency virus
(17). Although the symptoms of cryptococcosis can often be
suppressed by treatment with antifungal agents, in most cases the
infection is incurable and lifelong treatment is required
(29). Because control of iron uptake has decided the outcome
of infections in the model cases cited above, we investigated iron
uptake in C. neoformans with the hope of being able to
bolster nutritional immunity. We previously described two mechanisms by
which this organism reduces extracellular iron: expression of a cell
membrane ferric reductase and secretion of the nonspecific reductant
3-hydroxyanthranilic acid (22). In the present report, we
describe iron uptake physiologically. We chose to use a serotype D
strain because of the availability of both meiotic and molecular
analyses in the serotype D cryptococcal system.
 |
MATERIALS AND METHODS |
Yeast strains and culture conditions.
We used strain B3501,
MAT
, serotype D, obtained from the National Institutes of
Health culture collection. Cultures were stored on brain heart agar
slants, from which liquid cultures were started in 2% glucose-2%
yeast extract (GYE; Becton Dickinson and Co.) broth. Limited-iron
medium (LIM) contained, per liter, 20 g of glucose, 5 g of
asparagine, 400 mg of K2HPO4, 100 mg
of MgSO4 · 7H2O, 50 mg of
CaCl2 · 2H2O, 1 mg of thiamine, 57 µg
of boric acid, 396 µg of CuSO4 · 5H2O,
72 µg of MnCl2 · 4H2O, 4.2 mg of
ZnCl2, and 37 µg of
(NH4)6Mo7O24 · 4H2O. It was buffered with 50 mM
2-(N-morpholino)ethanesulfonic acid adjusted to pH 6.0 with
NaOH. Salts of polyvalent metals were dissolved in water treated with
Chelex-100 (Bio-Rad) and filter sterilized. Other components were
purified over a Chelex-100 column and filter sterilized. Cultures in
defined medium were started from stationary-phase cultures in GYE
broth, washed twice with LIM, and inoculated at a density of
106 cells/ml. All glassware was soaked in Citranox acid
detergent overnight and rinsed with distilled, deionized water before
use with LIM. Iron repletion was accomplished by adding the desired concentration of Fe(III)-hydroxyethylenediaminetriacetic acid (FeHEDTA) to LIM. All cultures were grown at room temperature with
agitation at 200 rpm. Platinum inhibition was achieved by use of LIM
saturated with platinum(II) chloride; the concentration was determined
by atomic absorption spectroscopy (Galbraith Laboratories, Knoxville,
Tenn.).
Iron uptake assays.
Cells were grown in LIM with or without
various concentrations of FeHEDTA to the late growth phase
(<2 × 107 cells/ml) or to the stationary phase. The
cells were washed twice and diluted in LIM to a concentration of 4 × 106 cells/ml. To assay ferrous iron uptake, an equal
volume of LIM containing 100 mM ascorbate and 1 mM dithiothreitol (DTT)
at pH 6.0 (LAD) was added to 5 ml of cells. To assay Fe(III)
uptake, an equal volume of LIM (without reductants) was added to 5 ml of cells. Iron was added to the cultures at the desired concentration as FeHEDTA diluted in LAD [for Fe(II)] or LIM [for
Fe(III)] containing 55FeCl3 (0.2 µCi;
New England Nuclear Corp.). Immediately upon the addition of iron, a
3-ml initial-time sample was filtered through a GF/A glass microfiber
filter (Whatman) and washed twice with 10 ml of 0.1 M disodium EDTA (pH
6.0). Cultures were incubated with agitation at 150 rpm and room
temperature for 20 min, after which a second 3-ml sample was obtained.
Counts on filters were determined with 10 ml of scintillation fluid
(Biosafe II; Research Products International) by use of a model 1410 liquid scintillation counter (Wallac). Uptake was calculated by
subtracting the counts per minute of the initial sample from that of
the 20-min sample and comparing the result to an internal standard.
Deferoxamine mesylate was a gift from the Ciba Corporation. Statistical
comparisons were done with Student's t test.
 |
RESULTS AND DISCUSSION |
Kinetics of Fe(II) uptake.
The uptake of Fe(II) was
studied with 55Fe in the presence of the reductants DTT and
ascorbate. Uptake was linear with respect to time for 40 min and linear
with respect to number of cells assayed for up to 107
cells/ml (data not shown). Suspensions of C. neoformans
grown in LIM were assayed for uptake in various concentrations of
Fe(II). Each concentration was studied in triplicate, several
experiments were performed, and a typical experiment is shown in Fig.
1. A log-log plot of uptake versus
concentration shows a steeply sloping portion well below 1 µM, a
shallowly sloping, relative plateau between 1 and 25 µM, and a second
steeply sloping portion above 25 µM (Fig. 1A). This pattern is
consistent with a combination of high- and low-affinity uptake systems,
as described for S. cerevisiae (6, 7), and
indicates saturation of the high-affinity uptake system in the range of
1 to 5 µM. A double-reciprocal plot indicated a
Km of approximately 0.6 µM for the
high-affinity system (Fig. 1B; data for a growth-phase culture are
shown). Clearly, the high-affinity uptake system is tuned to
concentrate ambient iron in the range of 0.1 to 1 µM very
efficiently. Because it is very difficult to reduce the iron content of
growth media below 100 nM, these data seem to explain why C. neoformans grows readily, even in iron-depleted media; in order to
observe the failure of growth due to iron limitation, we found it
necessary to use an avid synthetic chelator of Fe(II) or
Fe(III) (12, 13).

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 1.
Fe(II) uptake by growth-phase and stationary-phase
cells. (A) Velocity depicted as a function of concentration. A
logarithmic plot was used in order to encompass a 5-log-unit variation
in Fe(II) concentrations. Error bars indicate standard deviations.
(B) Double-reciprocal plot of low-concentration data from an
exponentially growing culture. The experiment was performed three
times, and representative results are shown.
|
|
We chose 1 µM Fe(II) as the standard concentration for assaying
the high-affinity system in order to minimize the effect of
changes in
substrate concentration. At 1 µM, the uptake of Fe(II)
was
110 ± 3 pmol/10
6 cells/h, close to the
Vmax for the high-affinity system. When
the
temperature of incubation was reduced to 4°C, high-affinity
uptake
was 96% inhibited (27 ± 5 versus 1 ± 0 pmol/10
6 cells/h; the experiment was performed in
triplicate), indicating
that active respiratory metabolism is required
for transport.
That inference was supported by the finding that 2 mM
KCN inhibited
uptake by 79% (38 ± 8 versus 8 ± 1 pmol/10
6 cells/h; the experiment was performed in
triplicate). These results
are very similar to those obtained for
S. cerevisiae, except that
for the latter, the
Km for high-affinity iron uptake is somewhat
lower (0.15 µM) (
7).
Regulation of ferrous transport.
Cultures in the late growth
phase (24-h incubation time) and in the stationary phase (72-h
incubation time) in LIM exhibited comparable uptake activities at all
concentrations of Fe(II) studied (Fig. 1). Cultures transferred
from GYE (approximately 25 µM Fe) to LIM (approximately 0.2 µM Fe) did not immediately express the high-affinity
(low-substrate-concentration) uptake system; such cultures began to
express that uptake system only after 10 h of growth in LIM,
reaching maximum activity at about 24 h (Fig.
2; an experiment with duplicate time
points is shown). This result suggests that the high-affinity uptake
system was regulated by iron in the culture and that the culture had
outgrown the iron stores left over from the complex medium. Indeed, we
observed that uptake activity was down regulated 50% after
24 h of growth in LIM containing 1 µM Fe(III) (data
not shown) and that both high-affinity and low-affinity
(high-concentration) uptake systems were down regulated 90% by growth
in 15 µM Fe(III), as shown in Fig.
3 [uptake was studied once at a range of
55Fe(II) concentrations; the result was confirmed by
four uptake studies at 1 µM 55Fe(II), each performed
in triplicate]. Thus, the high-affinity uptake system is potentially
resistant to iron overloading at up to 25 µM, partly because of
the saturation phenomenon, whereby increases in iron
concentrations from 1 to 25 µM result in very little
incremental uptake, and partly because the regulation of uptake
activity (presumably genetic regulation of expression of the ferrous
transporter) begins at about 1 µM ambient iron.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Expression of high-affinity uptake system following
transfer from GYE medium to LIM medium. Cells from a stationary-phase
culture in GYE were inoculated at 106/ml and agitated.
Growth was monitored optically at 700 nm, and high-affinity Fe(II)
uptake was measured periodically. Results represent averages of three
separate timed cultures assayed in duplicate. Error bars indicate
standard deviations.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 3.
Effect of Fe(III) in growth medium upon Fe(II)
uptake activity. Cells were grown in LIM with or without ( Fe) 15 µM
Fe, washed in LIM, and assayed for Fe(II) uptake at various
concentrations. (A) Double-logarithm plot. (B) Arithmetic plot of
low-concentration data.
|
|
Given the sensitivity of the high-affinity iron uptake system to
regulation by only 15 µM Fe, the utility of high-velocity
iron uptake
at high concentrations (25 to 200 µM) is not at all
clear, yet above
25 µM an upward curve in the concentration-velocity
plot suggests a
contribution by a low-affinity, high-velocity
uptake mechanism (Fig.
1,
3, and
4). The low-affinity system concentrated
approximately 1 nmol/10
6 cells/h at 200 µM Fe(II), and the lack of a
second plateau in
the plot suggests that the low-affinity mechanism is
not saturable.
This second system appeared to be down regulated during
growth
by the same relatively low concentration of iron (15 µM) as
that
which regulated the high-affinity system (Fig.
3A). Thus, if
low-affinity
uptake were not also regulated, the iron-replete plot
should have
converged upon the iron-depleted plot at high iron
concentrations
in the log-log plot, since the constant equal to the
saturated
high-affinity uptake system should represent a diminishing
fraction
of the increasing logarithms. Accordingly, both high- and
low-affinity
systems appeared to have been down regulated 1 log
unit by 15
µM Fe(III). Curiously, at 200 µM Fe(II),
the low-affinity system
of the high-iron culture transported about as
much iron (100 pmol/10
6 cells/h) as the
Vmax for the maximally induced high-affinity
system of the low-iron culture, making regulation of the high-affinity
system seem futile. One can assert that an Fe(II) concentration
of
100 µM may not be physiologic, but even with aerobic cultures
we have
observed such a concentration for a constitutive ferric
reductase
regulatory mutant (
11).
Dependence upon exogenous copper.
Perhaps the most striking
finding for the S. cerevisiae system has been the dependence
of iron uptake upon a copper-containing protein thought to function as
an oxidase (4). Indeed, there is evidence for the direct
association of a copper-containing protein with the ferrous transporter
in S. cerevisiae, and it is inferred that copper-containing
oxidases may be widely required for eukaryotic iron transport (15,
26). Nascent Fe(II) released from the cell membrane
ferric reductase is presumed to be reoxidized by the
copper-containing protein at the time of transport into the cell; thus,
the main uptake pathway may perhaps be called "reductive/oxidative." We assayed Fe(II) uptake in
copper-starved C. neoformans cultures. Cryptococcal LIM
normally contains 1.6 µM Cu(II). When this copper was not supplied,
24-h cultures reached optical densities 10% lower than those of
cultures containing 1.6 µM Cu(II). Under these conditions, the
high-affinity system was 90% suppressed, as shown in Fig.
4 (uptake was studied once at a range of
concentrations; the result was confirmed by an uptake study
performed in triplicate at 1 mM 55Fe). Thus, it seems
likely that a copper-containing factor is also required for
high-affinity iron uptake in C. neoformans.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of culture copper deprivation upon Fe(II)
uptake. Cells were grown in LIM containing 1.6 µM CuSO4
(+Cu) or in LIM formulated without CuSO4 ( Cu). (A)
Double-logarithm plot. (B) Arithmetic plot of low-concentration data.
|
|
Specificity for Fe(II) of the iron uptake step.
Iron
assimilation (iron-dependent growth) in C. neoformans
appears to require the reduction of Fe(III) to Fe(II) as a
first step (13, 22, 27). We defined two main mechanisms for
the reduction of extracellular Fe(III) prior to uptake. The first is a plasma membrane ferric reductase, and the second consists of
secreted ferric reductants, one of which has been identified as
3-hydroxyanthranilate. Expression of the enzyme and secretion of the
reductant are both down regulated by environmental iron, a
finding which supports the above hypothesis (22).
In our uptake assays, we usually fixed iron in the Fe(II) state
with the exogenous reducing agents ascorbic acid and DTT. We tested
whether reduction is required for physiologic iron uptake. When a
24-h growth-phase culture was assayed for the uptake of 1 µM
Fe(III) without the exogenous reductants DTT and ascorbic acid but
still in the presence of its culture supernatants, the uptake rate was
only slightly lower than that in the presence of the exogenous
reductants (no reductants, 118 ± 26 pmol/106 cells/h;
reductants, 144 ± 38; three experiments were performed in
triplicate; P = 0.3, not significant). However,
washing the cells twice in fresh LIM resulted in a 46% decrease in
iron uptake, presumably by the removal of secreted
3-hydroxyanthranilate (washed, no exogenous reductants, 60 ± 16 pmol/106 cells/h; exogenous reductants, 111 ± 8;
three experiments were performed in triplicate; P = 0.05). The substantial remaining uptake activity presumably depended
upon the reduction of extracellular Fe(III) by the cell membrane
ferric reductase (22). This hypothesis was tested in further
experiments with washed cells without exogenous reductants (Table
1, experiment A).
Bathophenanthroline disulfonate (BPDS) (1 mM), an avid chelator
of Fe(II), was found to abolish iron uptake quantitatively; the
mild oxidant potassium nitrosodisulfonate (1 mM) inhibited the uptake
of iron by 94%, although at this concentration it did not inhibit
growth. Thus, reduction of Fe(III) to Fe(II) appeared to be
essential for high-affinity uptake. Interestingly, the velocities at
which physiologic reduction and uptake occur are very different, for
the reduction of Fe(III) can occur in a burst at 60 nmol/106 cells/h (23) while the maximum velocity
for Fe(II) uptake is 120 pmol/106 cells/h, about
500-fold lower. Thus, it is possible for Fe(II) to accumulate in
the extracellular fluid, where it may represent a pool of reducing
equivalents available for electrochemical work, such as the reduction
of melanin (11).
Stimulation of iron uptake by deferoxamine.
Although
C. neoformans does not secrete siderophores,
its response to them is of considerable interest. We have observed that deferoxamine relieves iron starvation caused by the avid synthetic chelator ethylenediaminedi(o-hydroxyphenylacetic acid)
(12), while others have found deferoxamine to exacerbate
experimental cryptococcosis in the guinea pig (1). Thus,
C. neoformans behaves as though it expresses a receptor
for Fe(III)-deferoxamine. We tested the effect of 1 µM
deferoxamine mesylate (added 10 min prior to the experiment) upon the
uptake of Fe(III) by 24-h growth-phase cultures of C. neoformans. The experiment was performed without exogenous
reductants because deferoxamine is specific for Fe(III). The
threefold stimulation observed (Fig.
5) did not seem attributable to the
nonspecific solubilization of Fe(III) by deferoxamine, because iron
was always used with equimolar HEDTA, a synthetic iron chelator and
solubilizer. We tested whether deferoxamine-stimulated uptake was
independent of the copper-dependent uptake pathway but found that
deferoxamine-stimulated uptake was 90% abolished by growth without
copper (Fig. 5). Thus, deferoxamine-mediated uptake apparently proceeds
via the copper-dependent uptake pathway.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 5.
Stimulation of iron uptake by 1 µM deferoxamine (DFO).
Cultures grown in LIM with and without (Lim Cu) 1.6 µM
CuSO4 were washed and assayed for iron uptake without
exogenous reductants. The results are averages of two experiments
performed in triplicate. Error bars show standard deviations.
|
|
We also considered the relationship of deferoxamine to the iron
reduction step. The fate of Fe(III) in the
S. cerevisiae uptake
model is believed to be reduction
to Fe(II) by the cell membrane
ferric reductase, followed by
reoxidation by the copper-containing
uptake-linked oxidase
during transport (
4,
15,
26). Assuming
an equivalent pathway
in
C. neoformans, Fe(III) complexed by deferoxamine
may enter the uptake pathway either prior to the reductive step
or
following reoxidation. Since the ferric reductase is subject
to
inhibition by Pt(II)Cl
2 (
6), inhibition of
deferoxamine-mediated
iron uptake by Pt(II) would suggest that
deferoxamine does not
allow Fe(III) to bypass the reductive
step, while the maintenance
of deferoxamine-stimulated uptake in the
presence of Pt inhibition
of the reductase would suggest the donation
of Fe(III) by deferoxamine
after the copper-mediated oxidase step.
We found approximately
80% inhibition of the cryptococcal ferric
reductase by 4 µM Pt(II);
when we performed uptake experiments with
5.6 µM Pt(II), deferoxamine-stimulated
uptake was inhibited by Pt
(Table
1, experiment B). This result
suggests that the input of
Fe(III) by deferoxamine precedes the
enzyme-mediated ferric
reduction step. Moreover, because deferoxamine-stimulated
iron uptake
is abolished by copper starvation (see previous paragraph),
it is
doubly unlikely that the Fe(III)-deferoxamine complex bypasses
the copper-dependent oxidase step. Thus, a deferoxamine receptor
protein may be associated with the plasma membrane ferric reductase.
Alternatively, deferoxamine may simply be more efficient than
FeHEDTA at presenting Fe(III) to the ferric reductase. The
deferoxamine
stimulation of iron uptake that we observed with
C. neoformans is similar to observations made with
Rhizopus species, which cause
opportunistic infections
in deferoxamine-treated patients (
1).
It is not clear why
cases of deferoxamine-associated cryptococcosis
have not likewise been
reported.
 |
ACKNOWLEDGMENT |
This work was supported by the Department of Veterans Affairs.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Research
Service, Box 151, McGuire Veterans Affairs Medical Center, 1201 Broad
Rock Blvd., Richmond, VA 23249. Phone: (804) 675-5000, ext. 3641. Fax: (804) 675-5359. E-mail:
jacobson.eric_s{at}richmond.va.gov.
Editor:
T. R. Kozel
 |
REFERENCES |
| 1.
|
Boelaert, J. R.,
M. de Locht,
J. van Cutsem,
V. Kerrels,
B. Cantinieaux,
A. Verdonck,
H. W. van Landuyt, and Y.-J. Schneider.
1993.
Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo studies.
J. Clin. Invest.
91:1979-1986.
|
| 2.
|
Burt, W. R.
1982.
Identification of coprogen B and its breakdown products from Histoplasma capsulatum.
Infect. Immun.
35:990-996[Abstract/Free Full Text].
|
| 3.
|
Cartwright, G. E., and M. M. Wintrobe.
1952.
The anemia of infection.
Adv. Intern. Med.
5:165[Medline].
|
| 4.
|
Dancis, A.,
D. S. Yuan,
D. Haile,
C. Askwith,
D. Eide,
C. Moehle,
J. Kaplan, and R. D. Klausner.
1994.
Molecular characterization of a copper transport protein in S. cerevisiae: an unexpected role for copper in iron transport.
Cell
76:393-402[Medline].
|
| 5.
|
Deneer, H. G.,
V. Healey, and I. Boychuk.
1995.
Reduction of exogenous ferric iron by a surface-associated ferric reductase of Listeria spp.
Microbiology
141:1985-1992[Abstract/Free Full Text].
|
| 6.
|
Dix, D. R.,
J. T. Bridgham,
M. A. Broderius,
C. A. Byersdorfer, and D. J. Eide.
1994.
The FET4 gene encodes the low affinity Fe(II) transport protein of Saccharomyces cerevisiae.
J. Biol. Chem.
269:26092-26099[Abstract/Free Full Text].
|
| 7.
|
Eide, D.,
S. Davis-Kapan,
I. Jordan,
D. Sipe, and J. Kaplan.
1992.
Regulation of iron uptake in Saccharomyces cerevisiae.
J. Biol. Chem.
267:20774-20781[Abstract/Free Full Text].
|
| 8.
|
Emery, H. S.,
C. P. Shelburne,
J. P. Bowman,
P. G. Fallon,
C. A. Schultz, and E. S. Jacobson.
1994.
Genetic study of oxygen resistance and melanization in Cryptococcus neoformans.
Infect. Immun.
62:5694-5697[Abstract/Free Full Text].
|
| 9.
|
Gordeuk, V.,
P. Thuma,
G. Brittenham,
C. McLaren,
D. Parry,
A. Backenstose,
G. Biemba,
R. Msiska,
L. Holmes,
E. McKinley,
L. Vargas,
R. Gilkeson, and A. A. Poltera.
1992.
Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria.
N. Engl. J. Med.
327:1473-1477[Abstract].
|
| 10.
|
Jacobson, E. S., and H. S. Emery.
1991.
Catecholamine uptake, melanization, and oxygen toxicity in Cryptococcus neoformans.
J. Bacteriol.
173:401-403[Abstract/Free Full Text].
|
| 11.
|
Jacobson, E. S., and J. D. Hong.
1997.
Redox buffering by melanin and Fe(II) in Cryptococcus neoformans.
J. Bacteriol.
179:5340-5346[Abstract/Free Full Text].
|
| 12.
|
Jacobson, E. S., and M. J. Petro.
1987.
Extracellular iron chelation in Cryptococcus neoformans.
J. Med. Vet. Mycol.
25:415-418[Medline].
|
| 13.
|
Jacobson, E. S., and S. E. Vartivarian.
1992.
Iron assimilation in Cryptococcus neoformans.
J. Med. Vet. Mycol.
30:443-450[Medline].
|
| 14.
|
Johnson, W.,
L. Varner, and M. Poch.
1991.
Acquisition of iron by Legionella pneumophila: role of iron reductase.
Infect. Immun.
59:2376-2381[Abstract/Free Full Text].
|
| 15.
|
Kaplan, J., and T. V. O'Halloran.
1996.
Iron metabolism in eukaryotes: Mars and Venus at it again.
Science
271:1510-1512[Medline].
|
| 16.
|
LeSuisse, E.,
F. Raguzzi, and R. R. Crichton.
1987.
Iron uptake by the yeast Saccharomyces cerevisiae: involvement of a reduction step.
J. Gen. Microbiol.
133:3229-3236[Abstract/Free Full Text].
|
| 17.
|
Levitz, S. M.
1991.
The ecology of Cryptococcus neoformans and the epidemiology of cryptococcosis.
Rev. Infect. Dis.
13:1163-1169[Medline].
|
| 18.
|
Marschner, H.,
V. Romheld, and M. Kissel.
1986.
Different strategies in higher plants in mobilization and uptake of iron.
J. Plant Nutr.
9:695-713.
|
| 19.
|
Mickelsen, P. A., and P. F. Sparling.
1981.
Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from transferrin and iron compounds.
Infect. Immun.
33:555-564[Abstract/Free Full Text].
|
| 20.
|
Morrissey, J. A.,
P. H. Williams, and A. M. Cashmore.
1996.
Candida albicans has a cell-associated ferric-reductase activity which is regulated in response to levels of iron and copper.
Microbiology
142:485-492[Abstract/Free Full Text].
|
| 21.
|
Neilands, J. B.
1981.
Microbial iron compounds.
Annu. Rev. Biochem.
50:715-731[Medline].
|
| 22.
|
Nyhus, K. J., and E. S. Jacobson.
1996.
Ferric reduction by Cryptococcus neoformans.
Infect. Immun.
65:434-438[Abstract].
|
| 23.
|
Olsen, R. A.,
J. C. Brown,
J. H. Bennett, and D. Blume.
1982.
Reduction of Fe3+ as it relates to Fe chlorosis.
J. Plant Nutr.
5:433-445.
|
| 24.
|
Pidcock, K. A.,
J. A. Wooten,
B. A. Daley, and T. L. Stull.
1988.
Iron acquisition by Haemophilus influenzae.
Infect. Immun.
56:721-725[Abstract/Free Full Text].
|
| 25.
|
Robins-Browne, R. M., and J. K. Prpic.
1985.
Effects of iron and desferrioxamine on infections with Yersinia enterocolitica.
Infect. Immun.
47:774-779[Abstract/Free Full Text].
|
| 26.
|
Stearman, R.,
D. S. Yuan,
Y. Yamaguchi-Iwai,
R. D. Klausner, and A. Dancis.
1996.
A permease-oxidase complex involved in high-affinity iron uptake in yeast.
Science
271:1552-1557[Abstract].
|
| 27.
|
Vartivarian, S. E.,
R. E. Cowart,
E. J. Anaissie,
T. Tashiro, and H. A. Sprigg.
1995.
Iron acquisition by Cryptococcus neoformans.
J. Med. Vet. Mycol.
33:151-156[Medline].
|
| 28.
|
Weinberg, E. D.
1978.
Iron and infection.
Microbiol. Rev.
42:45-66[Free Full Text].
|
| 29.
|
Zugar, A.,
E. Louis,
R. S. Holzman, et al.
1986.
Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment.
Ann. Intern. Med.
104:234-240.
|
Infection and Immunity, September 1998, p. 4169-4175, Vol. 66, No. 9
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tangen, K. L., Jung, W. H., Sham, A. P., Lian, T., Kronstad, J. W.
(2007). The iron- and cAMP-regulated gene SIT1 influences ferrioxamine B utilization, melanization and cell wall structure in Cryptococcus neoformans. Microbiology
153: 29-41
[Abstract]
[Full Text]
-
Hissen, A. H. T., Wan, A. N. C., Warwas, M. L., Pinto, L. J., Moore, M. M.
(2005). The Aspergillus fumigatus Siderophore Biosynthetic Gene sidA, Encoding L-Ornithine N5-Oxygenase, Is Required for Virulence. Infect. Immun.
73: 5493-5503
[Abstract]
[Full Text]
-
Tenney, A. E., Brown, R. H., Vaske, C., Lodge, J. K., Doering, T. L., Brent, M. R.
(2004). Gene prediction and verification in a compact genome with numerous small introns. Genome Res
14: 2330-2335
[Abstract]
[Full Text]
-
Giles, S. S., Czuprynski, C. J.
(2004). Extracellular Calcium and Magnesium, but Not Iron, Are Needed for Optimal Growth of Blastomyces dermatitidis Yeast Form Cells In Vitro. CVI
11: 426-429
[Abstract]
[Full Text]
-
Hissen, A. H. T., Chow, J. M. T., Pinto, L. J., Moore, M. M.
(2004). Survival of Aspergillus fumigatus in Serum Involves Removal of Iron from Transferrin: the Role of Siderophores. Infect. Immun.
72: 1402-1408
[Abstract]
[Full Text]
-
Timmerman, M. M., Woods, J. P.
(2001). Potential Role for Extracellular Glutathione-Dependent Ferric Reductase in Utilization of Environmental and Host Ferric Compounds by Histoplasma capsulatum. Infect. Immun.
69: 7671-7678
[Abstract]
[Full Text]
-
AHLUWALIA, M., BRUMMER, E., SRIDHAR, S., SINGH, R, STEVENS, D.A.
(2001). Isolation and characterisation of an anticryptococcal protein in human cerebrospinal fluid. J Med Microbiol
50: 83-89
[Abstract]
[Full Text]
-
Sridhar, S., Ahluwalia, M., Brummer, E., Stevens, D. A.
(2000). Characterization of an Anticryptococcal Protein Isolated from Human Serum. Infect. Immun.
68: 3787-3791
[Abstract]
[Full Text]
-
Taramelli, D., Brambilla, S., Sala, G., Bruccoleri, A., Tognazioli, C., Riviera-Uzielli, L., Boelaert, J. R.
(2000). Effects of Iron on Extracellular and Intracellular Growth of Penicillium marneffei. Infect. Immun.
68: 1724-1726
[Abstract]
[Full Text]
-
Timmerman, M. M., Woods, J. P.
(1999). Ferric Reduction Is a Potential Iron Acquisition Mechanism for Histoplasma capsulatum. Infect. Immun.
67: 6403-6408
[Abstract]
[Full Text]
-
Howard, D. H.
(1999). Acquisition, Transport, and Storage of Iron by Pathogenic Fungi. Clin. Microbiol. Rev.
12: 394-404
[Abstract]
[Full Text]
-
Nyhus, K. J., Jacobson, E. S.
(1999). Genetic and Physiologic Characterization of Ferric/Cupric Reductase Constitutive Mutants of Cryptococcus neoformans. Infect. Immun.
67: 2357-2365
[Abstract]
[Full Text]